Confidential Investment Memorandum · 2026
The Body Has a System No One Has Commercialised at Scale. Until Now.
FasciaClinics is building the world's first franchise network for fascia-based bodywork — a €5.5 trillion wellness market with no dominant player, no category leader, and no comparable exit in the last decade.
Investment Thesis
Proven model — 16 years of R&D, 100,000+ treatments, profitable franchise units
Proprietary technology — Atlasbalans, patented, German Design Award 2020
10-year head start — no competitor holds all four moats simultaneously
Asset-light expansion — franchisee bears operational risk, we earn royalties
International traction — Japan under active negotiation, USA in preparation
Request Full Investment Documentation
This material is exclusively directed to qualified investors. Please provide your details to access the full investment memorandum, financial model, and supporting documentation.
GHL FORM PLACEHOLDER
GoHighLevel embed will be placed here
No commitment required. We will respond within one business day.
Key Metrics
100,000+
Treatments delivered
16 yrs
R&D & clinical experience
500+
Certified specialists
4,800+
Google reviews
250 MSEK
Pre-money valuation
12.50 SEK
Price per share
The Opportunity in Brief
The Problem
Modern medicine has fragmented the body into specialities. No one sees the whole. Fascia — the connective tissue system linking everything — is the missing piece. Conditions like frozen shoulder, chronic pain, and restricted mobility remain poorly served.
The Solution
FasciaClinics delivers standardised fascia-based treatments through a franchise network. Proprietary Atlasbalans technology, a reproducible protocol, and a plug-and-play franchise system enable rapid, quality-assured expansion.
The Business Model
Three revenue streams: (1) royalty on every treatment at every active clinic worldwide, (2) upfront fee per new unit opened, (3) master franchise licence fee per new country. Asset-light, recurring, and globally scalable.
The Raise
FasciaClinics International is raising capital to fund international expansion, Atlasbalans production scale-up, and the Fascia Knowledge Platform. Pre-money valuation: 265 MSEK. Price per share: 12.50 SEK.
